Physician profile
Ati Hakimi
NPI 1881635654
$5,253.69
in general payments reported to CMS, 2019-2025
24 companies · $752 in 2025
The $752 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $387 · 2021: $242 · 2022: $811 · 2023: $1,217 · 2024: $1,062 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $709.54 | 2022-2025 | Opzelura, Opzelura |
| Ucb, INC. | $526.27 | 2022-2025 | Briviact, Cimzia |
| Amgen INC. | $465.52 | 2020-2024 | Uplizna |
| Genzyme Corporation | $368.55 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $340.06 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $315.51 | 2022-2024 | Sotyktu |
| Glaxosmithkline, LLC. | $223.26 | 2021-2024 | |
| Biogen, INC. | $219.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $202.96 | 2019-2020 | |
| Abbvie INC. | $149.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.66 | 2022 | |
| Akcea Therapeutics, INC. | $142.43 | 2019 | |
| Abbott Laboratories | $140.00 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $139.46 | 2023 | Eluvia |
| Genentech, INC. | $129.24 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.97 | 2022 | |
| Viiv Healthcare Company | $124.84 | 2023 | Dovato |
| Alexion Pharmaceuticals, INC. | $121.96 | 2024 | Strensiq |
| Gilead Sciences, INC. | $121.96 | 2023 | Veklury |
| Lilly USA, LLC | $120.04 | 2019 | |
| Kyowa Kirin, INC. | $119.34 | 2025 | |
| Amarin Pharma, INC. | $116.41 | 2020 | |
| Novo Nordisk INC | $110.65 | 2023 | |
| Medtronic, INC. | $72.81 | 2025 | Mazor X System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ati Hakimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.